Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Terron A, Bal-Price A, Paini A, Monnet-Tschudi F, Bennekou SH; EFSA WG EPI1 Members, Leist M, Schildknecht S.

Arch Toxicol. 2018 Jan;92(1):41-82. doi: 10.1007/s00204-017-2133-4. Epub 2017 Dec 5. Review.

2.

International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine.

Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL.

J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017. Review.

3.

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

Petrov D, Mansfield C, Moussy A, Hermine O.

Front Aging Neurosci. 2017 Mar 22;9:68. doi: 10.3389/fnagi.2017.00068. eCollection 2017. Review.

4.

Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice.

Shafaroodi H, Shahbek F, Faizi M, Ebrahimi F, Moezi L.

Iran J Pharm Res. 2016 Fall;15(4):843-850.

5.

Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments.

Tefera TW, Borges K.

Front Neurosci. 2017 Jan 10;10:611. doi: 10.3389/fnins.2016.00611. eCollection 2016. Review.

6.

Effects of creatine monohydrate supplementation and exercise on depression-like behaviors and raphe 5-HT neurons in mice.

Ahn NR, Leem YH, Kato M, Chang HK.

J Exerc Nutrition Biochem. 2016 Sep;20(3):24-31. Epub 2016 Sep 30.

7.
8.

Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Bedlack RS, Joyce N, Carter GT, Paganoni S, Karam C.

Neurol Clin. 2015 Nov;33(4):909-36. doi: 10.1016/j.ncl.2015.07.008. Epub 2015 Sep 8. Review.

9.

Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study.

Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF.

J Dual Diagn. 2015;11(3-4):189-202. doi: 10.1080/15504263.2015.1100471.

10.

A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions.

Kumar A, Singh A.

Front Pharmacol. 2015 Sep 24;6:206. doi: 10.3389/fphar.2015.00206. eCollection 2015. Review.

11.

A review of creatine supplementation in age-related diseases: more than a supplement for athletes.

Smith RN, Agharkar AS, Gonzales EB.

F1000Res. 2014 Sep 15;3:222. doi: 10.12688/f1000research.5218.1. eCollection 2014. Review.

12.

Effects of dietary creatine supplementation on systemic microvascular density and reactivity in healthy young adults.

Moraes Rd, Van Bavel D, Moraes BS, Tibiriçá E.

Nutr J. 2014 Dec 15;13(1):115. doi: 10.1186/1475-2891-13-115.

13.

Both creatine and its product phosphocreatine reduce oxidative stress and afford neuroprotection in an in vitro Parkinson's model.

Cunha MP, Martín-de-Saavedra MD, Romero A, Egea J, Ludka FK, Tasca CI, Farina M, Rodrigues AL, López MG.

ASN Neuro. 2014 Nov 24;6(6). pii: 1759091414554945. doi: 10.1177/1759091414554945. Print 2014.

14.

Early Expression of Parkinson's Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats.

Villeneuve LM, Purnell PR, Boska MD, Fox HS.

Mol Neurobiol. 2016 Jan;53(1):171-186. doi: 10.1007/s12035-014-8927-y. Epub 2014 Nov 25.

15.
16.

Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Herradón G, Pérez-García C.

Br J Pharmacol. 2014 Feb;171(4):837-48. doi: 10.1111/bph.12312. Review.

17.

A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, Bae S, Renshaw PF.

Am J Psychiatry. 2012 Sep;169(9):937-945. doi: 10.1176/appi.ajp.2012.12010009.

18.

Creatine pretreatment protects cortical axons from energy depletion in vitro.

Shen H, Goldberg MP.

Neurobiol Dis. 2012 Aug;47(2):184-93. doi: 10.1016/j.nbd.2012.03.037. Epub 2012 Apr 11.

19.

Aβ oligomers-induced toxicity is attenuated in cells cultured with NbActiv4™ medium.

Zhou Y, Klein WL.

Neurotox Res. 2012 Nov;22(4):335-44. Epub 2012 Mar 23.

20.

The promise of neuroprotective agents in Parkinson's disease.

Seidl SE, Potashkin JA.

Front Neurol. 2011 Nov 21;2:68. doi: 10.3389/fneur.2011.00068. eCollection 2011. Erratum in: Front Neurol. 2013;7:69.

Supplemental Content

Support Center